0R15 7835.9976 0.0% 0R1E 10264.998 0.0% 0M69 24553.9297 95.0272% 0R2V 213.0 0.7092% 0QYR 1789.0 0.0% 0QYP 389.0 1.8325% 0RUK None None% 0RYA 1741.0 -0.5143% 0RIH 164.5 0.8275% 0RIH 163.28 0.0797% 0R1O 197.25 9837.0277% 0R1O None None% 0QFP 10420.0 106.746% 0M2Z 255.95 -1.5103% 0VSO 46.05 5.6193% 0R1I None None% 0QZI 605.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 195.87 1.8194%
Last update at 2025-03-14T17:37:00Z
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
Fri 10 Mar 23, 01:35 PMLife Sciences Virtual Investor Forum Agenda Announced for March 9th
Tue 07 Mar 23, 01:35 PM| Breakdown | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 |
| Income before tax | -1.63430M | - |
| Minority interest | - | - |
| Net income | -1.61542M | - |
| Selling general administrative | 0.94M | - |
| Selling and marketing expenses | - | - |
| Gross profit | 0.00000M | - |
| Reconciled depreciation | 0.00000M | - |
| Ebit | -1.63430M | -0.38298M |
| Ebitda | -1.63430M | - |
| Depreciation and amortization | 0.00000M | - |
| Non operating income net other | - | - |
| Operating income | -1.63430M | - |
| Other operating expenses | 1.63M | - |
| Interest expense | - | 0.00000M |
| Tax provision | -0.01889M | - |
| Interest income | - | - |
| Net interest income | - | - |
| Extraordinary items | - | - |
| Non recurring | - | - |
| Other items | - | - |
| Income tax expense | -0.01889M | - |
| Total revenue | 0.00000M | - |
| Total operating expenses | 1.63M | - |
| Cost of revenue | 0.00000M | - |
| Total other income expense net | - | - |
| Discontinued operations | - | - |
| Net income from continuing ops | -1.61542M | - |
| Net income applicable to common shares | -1.61542M | -0.68807M |
| Preferred stock and other adjustments | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 |
| Total assets | 7.77M | 4.56M |
| Intangible assets | 5.06M | 1.20M |
| Earning assets | - | - |
| Other current assets | - | - |
| Total liab | 0.56M | 0.48M |
| Total stockholder equity | 7.21M | 4.08M |
| Deferred long term liab | - | - |
| Other current liab | 0.21M | 0.15M |
| Common stock | 1.29M | 0.72M |
| Capital stock | 1.29M | 0.72M |
| Retained earnings | -2.54873M | -0.91432M |
| Other liab | 0.28M | 0.28M |
| Good will | 0.28M | 0.28M |
| Other assets | - | - |
| Cash | 2.32M | 0.90M |
| Cash and equivalents | - | - |
| Total current liabilities | 0.28M | 0.20M |
| Current deferred revenue | - | - |
| Net debt | -2.32297M | -0.89972M |
| Short term debt | - | - |
| Short long term debt | - | - |
| Short long term debt total | - | - |
| Other stockholder equity | 8.46M | 4.28M |
| Property plant equipment | - | - |
| Total current assets | 2.42M | 3.08M |
| Long term investments | - | - |
| Net tangible assets | 1.86M | 2.60M |
| Short term investments | - | - |
| Net receivables | 0.10M | 2.15M |
| Long term debt | - | - |
| Inventory | - | - |
| Accounts payable | 0.07M | 0.04M |
| Total permanent equity | - | - |
| Noncontrolling interest in consolidated entity | - | - |
| Temporary equity redeemable noncontrolling interests | - | - |
| Accumulated other comprehensive income | - | - |
| Additional paid in capital | - | - |
| Common stock total equity | - | - |
| Preferred stock total equity | - | - |
| Retained earnings total equity | - | - |
| Treasury stock | - | - |
| Accumulated amortization | - | - |
| Non currrent assets other | - | - |
| Deferred long term asset charges | - | - |
| Non current assets total | 5.34M | 1.48M |
| Capital lease obligations | - | - |
| Long term debt total | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 |
| Investments | -0.10348M | - |
| Change to liabilities | 0.06M | 0.10M |
| Total cashflows from investing activities | -0.10348M | -0.82967M |
| Net borrowings | - | - |
| Total cash from financing activities | 3.10M | 3.47M |
| Change to operating activities | - | - |
| Net income | -1.63430M | -0.68807M |
| Change in cash | 1.42M | 0.67M |
| Begin period cash flow | 0.90M | - |
| End period cash flow | 2.32M | 0.90M |
| Total cash from operating activities | -1.57748M | -1.96728M |
| Issuance of capital stock | 3.12M | - |
| Depreciation | 0.00000M | - |
| Other cashflows from investing activities | - | - |
| Dividends paid | - | - |
| Change to inventory | 0.00000M | 0.00696M |
| Change to account receivables | -0.02032M | -1.59798M |
| Sale purchase of stock | - | - |
| Other cashflows from financing activities | -0.01899M | -0.11955M |
| Change to netincome | -0.00149M | 0.21M |
| Capital expenditures | 0.00000M | 0.00000M |
| Change receivables | - | - |
| Cash flows other operating | - | - |
| Exchange rate changes | - | - |
| Cash and cash equivalents changes | - | - |
| Change in working capital | 0.04M | - |
| Stock based compensation | 0.00843M | - |
| Other non cash items | 0.00897M | - |
| Free cash flow | -1.57748M | - |
Sector: Healthcare Industry: Biotechnology
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ROQ Roquefort Investments PLC |
0.30 18.75% | 1.90 | - | - | 48.43 | 1.40 | 38.31 | -5.187 |
| ONT Oxford Nanopore Technologies Ltd |
-1.6 1.57% | 100.20 | - | - | 10.88 | 2.75 | 8.77 | -16.7946 |
| GNS Genus PLC |
70.00 3.72% | 1950.00 | 42.59 | 25.71 | 2.08 | 2.46 | 2.31 | 16.39 |
| PRTC PureTech Health plc |
2.80 2.20% | 130.00 | - | - | 35.55 | 1.04 | 95.87 | -4.5333 |
| AVCT Avacta Group PLC |
1.00 2.63% | 39.00 | - | - | 23.19 | 14.78 | 20.75 | -10.4566 |
Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action. Roquefort Therapeutics plc was incorporated in 2020 and is based in London, the United Kingdom.
Eccleston Yards, London, United Kingdom, SW1W 9NF
| Name | Title | Year Born |
|---|---|---|
| Mr. Stephen Paul West B.Com, CA | Exec. Chairman | 1973 |
| Mr. Trevor Ajanthan Reginald | CEO & Exec. Director | NA |
| Prof. Martin J. Evans FRS | Group Chief Scientific Officer & Exec. Director | NA |
| Dr. Armand Keating M.D. | Independent Chief Medical Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...